MedTrace Logo

Safety and Efficacy Study of HGP1207 in Patients With Pulmonary Hypertension

NCT01913847 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2017-11-27

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety and clinical efficacy of HGP1207 (Sildenafil) in subjects with pulmonary hypertension associated with systolic heart failure.

Conditions

  • Pulmonary Hypertension
  • Systolic Dysfunction

Interventions

DRUG

Sildenafil

Oral sildenafil 20 mg TID for 12 weeks

DRUG

Placebo

Oral placebo TID for 12 weeks

Sponsors & Collaborators

  • Hanmi Pharmaceutical Company Limited

    lead INDUSTRY

Principal Investigators

  • Kyu Hyung Ryu, M.D. Ph.D. · Hallym University Dongtan Sacred Heart Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01913847 on ClinicalTrials.gov